Superselective transarterial radioembolization for the treatment of hepatocellular carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Superselective transarterial radioembolization (TARE) refers the delivery of Y90 at the tumor-feeding segmental or subsegmental arteries. The purpose of TARE would be delivering high dose in the tumor while saving as much normal parenchyma as possible. This concept is similar to the radiation segmentectomy. To identify all tumor feeders, thorough angiography and cone-beam computed tomography are essential. Reported target dose of radiation segmentectomy ranges 222.6–521 Gy. After superselective TARE, the treated segments can show persistent enhancement, and then atrophy combined with capsular retraction. Superselective TARE promises favorable outcomes. It’s reported objective response rates range 64%–95% and toxicities are tolerable in most cases. In conclusion, superselective TARE is a very safe modality for the treatment of HCCs with favorable outcome close to the curative-intent treatments in selected patients.
Abstract
Superselective transarterial radioembolization (TARE) refers the delivery of Y90 at the tumor-feeding segmental or subsegmental arteries. The purpose of TARE would be delivering high dose in the tumor while saving as much normal parenchyma as possible. This concept is similar to the radiation segmentectomy. To identify all tumor feeders, thorough angiography and cone-beam computed tomography are essential. Reported target dose of radiation segmentectomy ranges 222.6–521 Gy. After superselective TARE, the treated segments can show persistent enhancement, and then atrophy combined with capsular retraction. Superselective TARE promises favorable outcomes. It’s reported objective response rates range 64%–95% and toxicities are tolerable in most cases. In conclusion, superselective TARE is a very safe modality for the treatment of HCCs with favorable outcome close to the curative-intent treatments in selected patients.
참고문헌 (24)
- Mattiuzzi C, "Current cancer epidemiology", J Epidemiol Glob Health, 9, pp.217~222 (2019)
- Forner A, "Hepatocellular carcinoma", Lancet, 379, pp.1245~1255 (2012)
- Bruix J, "Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma", Gastroenterology, 150, pp.835~853 (2016)
- Chow PKH, "SIRveNIB:selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
- Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
- Dawson LA, "Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies", J Clin Oncol, 18, pp.2210~2218 (2000)
- Dawson LA, "Analysis of radiation-induced liver disease using the Lyman NTCP model", Int J Radiat Oncol Biol Phys, 53, pp.810~821 (2002)
- Padia SA, "Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity", J Vasc Interv Radiol, 25, pp.1067~1073 (2014)
- Kim HC, "Combination of 1st and 2nd week dosing of glass yttrium-90 microspheres for superselective radioembolization", In Vivo, 34, pp.2763~2768 (2020)
- Miyayama S, "Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome", J Vasc Interv Radiol, 27, pp.1269~1278 (2016)
- Riaz A, "Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization", Int J Radiat Oncol Biol Phys, 79, pp.163~171 (2011)
- Lee IJ, "Cone-beam computed tomography (CBCT) hepatic arteriography in chemoembolization for hepatocellular carcinoma: performance depicting tumors and tumor feeders", Cardiovasc Intervent Radiol, 38, pp.1218~1230 (2015)
- Kao YH, "Image-guided personalized predictive dosimetry by artery-specific SPECT", CT partition modeling for safe and effective 90Y radioembolization, 2012, pp.53, 559~566
- Vouche M, "Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy", Hepatology, 60, pp.192~201 (2014)
- Kim HC, "Feasibility of boosted radioembolization for hepatocellular carcinoma larger than 5 cm", J Vasc Interv Radiol, 30, pp.1~8 (2019)
- Salem R, "Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study", Hepatology (2021)[DOI]
- Lau WY, "Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90resin microspheres", Int J Radiat Oncol Biol Phys, 82, pp.401~407 (2012)
- McGregor H, "Quantitative assessment of the hemodynamic effects of intra-arterial nitroglycerin on hepatocellular carcinoma using two-dimensional perfusion angiography", J Vasc Interv Radiol, 32, pp.198~203 (2021)
- Liu YS, "Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma:five-year retrospective study", Clin Res Hepatol Gastroenterol, 42, pp.542~552 (2018)
- Malhotra A, "Radiation segmentectomy and radiation lobectomy:a practical review of techniques", Tech Vasc Interv Radiol, 22, pp.49~57 (2019)
- Riaz A, "Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres", Hepatology, 49, pp.1185~1193 (2009)
- Atassi B, "Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay", Radiographics, 28, pp.81~99 (2008)
- Biederman DM, "Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study", Radiology, 283, pp.895~905 (2017)
- Biederman DM, "Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma", J Vasc Interv Radiol, 29, pp.30~37.e2 (2018)